Cryoport, Inc. (CYRX)
| Market Cap | 507.00M |
| Revenue (ttm) | 176.18M |
| Net Income (ttm) | 70.30M |
| Shares Out | 50.20M |
| EPS (ttm) | 1.40 |
| PE Ratio | 7.19 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 418,033 |
| Open | 10.34 |
| Previous Close | 10.38 |
| Day's Range | 9.98 - 10.40 |
| 52-Week Range | 5.31 - 11.45 |
| Beta | 1.69 |
| Analysts | Strong Buy |
| Price Target | 13.31 (+31.78%) |
| Earnings Date | May 4, 2026 |
About CYRX
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company’s Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network. The comp... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for CYRX stock is "Strong Buy." The 12-month stock price target is $13.31, which is an increase of 31.78% from the latest price.
News
Cryoport to Report First Quarter 2026 Financial Results on May 4, 2026
NASHVILLE, Tenn., April 20, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for ...
Cryoport Earnings Call Transcript: Q4 2025
Full year 2025 revenue exceeded guidance at $176.2M, driven by strong growth in commercial cell and gene therapy and life sciences services. 2026 guidance targets $190–$194M revenue and positive adjusted EBITDA in the second half, with continued innovation and global expansion supporting future growth.
Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results
FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidance Life Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServic...
Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
NASHVILLE, Tenn., Feb. 17, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sci...
Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series
Self-Sustaining Fusion® 800 Series Cryogenic Freezer Delivers High-Capacity Storage, Flexibility, and Cost Benefits in Limited Space Environments NASHVILLE, Tenn., Feb. 11, 2026 /PRNewswire/ -- Cryop...
Cryoport Systems Wins 2025 BioTech Breakthrough Award For “BioServices Innovation of the Year”
Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around th...
Cryoport Earnings Call Transcript: Q3 2025
Double-digit revenue growth continued in both core segments, with commercial cell and gene therapy revenue up 36% year-over-year. Updated 2025 revenue guidance to $170–$174 million, targeting positive adjusted EBITDA by year-end, and significant operating leverage expected in 2026–2027.
Cryoport Reports Strong Q3 Results, Raises FY25 Outlook
Cryoport Inc (NASDAQ:CYRX) reported third-quarter financial results after the market close on Tuesday. Here's a rundown of the temperature-controlled supply chain solutions company's report.
Cryoport Reports Third Quarter 2025 Financial Results
Third quarter revenue increased 15% year-over-year to $44.2 million Commercial Cell & Gene Therapy revenue increased 36% year-over-year to $8.3 million Life Sciences Services revenue grew 16% year-ove...
Cryoport Continues to Set New Benchmarks for the Global Regenerative Medicine Supply Chain
First Global Supply Chain Solutions Company to Achieve ISO 21973 Certification, Ensuring Highest Transport Safety, Traceability, and Integrity Standards for Cell and Gene Therapies NASHVILLE, Tenn. , ...
Cryoport to Report Third Quarter 2025 Financial Results on November 4, 2025
NASHVILLE, Tenn. , Oct. 21, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, to...
MVE Biological Solutions, A Cryoport Company, Introduces Real-Time Integrated Condition Monitoring Systems For Cryogenic Dewars
Connected, Intelligent Condition Monitoring Assets that Safeguard Vital Life Science Materials Mark MVE's First Step in its Real-Time Integrated Systems Evolution NASHVILLE, Tenn. , Oct. 7, 2025 /PRNe...
Cryoport Systems Expands Global Footprint with New Global Supply Chain Center in Paris, France
The 55,000-Square-Foot Facility is the Latest Addition to Cryoport Systems' Global Supply Chain Center Network Designed to Support Complex Life Sciences Supply Chain Needs, Including Biologistics, Bio...
Cryoport Earnings Call Transcript: Q2 2025
Double-digit revenue growth in Q2 2025 was driven by strong gains in Life Sciences Services and Products, improved margins, and a transformative partnership with DHL. Guidance for 2025 is reaffirmed, with a robust balance sheet and continued leadership in cell and gene therapy supply chain solutions.
Cryoport Reports Second Quarter 2025 Financial Results
Second quarter revenue increased 14% year-over-year to $45.5 million Commercial Cell & Gene Therapy revenue increased 33% year-over-year to $8.7 million Life Sciences Services revenue rose 21% year-ov...
Cryoport to Report Second Quarter 2025 Financial Results on August 5, 2025
NASHVILLE, Tenn. , July 22, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, to...
Cryoport's MVE Biological Solutions Introduces Next Generation Vapor Shippers
New SC vapor shipper series improves reliability through extended hold times and patented impact-absorbing and Vapor Shield Technology NASHVILLE, Tenn. , July 8, 2025 /PRNewswire/ -- Cryoport, Inc. (N...
Cryoport Completes CRYOPDP Divestiture and Commences Strategic Partnership with DHL Group
NASHVILLE, Tenn. , June 12, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leader in temperature-controlled supply chain solutions for the Life Sciences, with a fo...
Cryoport Earnings Call Transcript: Q1 2025
Q1 revenue grew 10% year-over-year to $41M, led by 17% growth in life sciences services and 33% growth in commercial cell and gene therapy revenue. Strategic partnership with DHL and the sale of CryoPDP for $195M will strengthen global reach and financials. FY25 revenue guidance is $165M–$172M.
Cryoport Reports First Quarter 2025 Financial Results
Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over year Q1 2025 revenue from continuing operations of $41.0 million, up 10% year over year Supporting 711 global clinical trials a...
Cryoport to Report First Quarter 2025 Financial Results on May 7, 2025
NASHVILLE, Tenn. , April 24, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global provider of supply chain solutions for the life sciences sector, today announced...
DHL Group acquires CRYOPDP from Cryoport to strengthen "DHL Health Logistics"
DHL to acquire 100% of CRYOPDP, a leading specialty courier providing logistics services for clinical trials, biopharma, and cell & gene therapies. This acquisition enhances DHL's capabilities in spec...
Cryoport Transcript: Investor Update
A strategic partnership with DHL, including the sale of CRYOPDP for $195 million, will accelerate growth, enhance global reach, and improve margins, with 2025 revenue guidance set at $165–$173 million. The move sharpens focus on cell and gene therapy and strengthens financial flexibility.
Cryoport to Host Investor Call to Discuss Recent Strategic Agreement and Transformative Transaction Today, March 31, 2025, at 8:30 a.m. ET
NASHVILLE, Tenn. , March 31, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences sector, today announced t...
Cryoport's MVE Biological Solutions Expands High-Efficiency Cryogenic Freezer Series With Answer to Evolving Needs of Fertility Clinics, Biorepositories and Clinical Laboratories
NASHVILLE, Tenn. , March 12, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in supply chain solutions for the life sciences, today announced the laun...